Abstract 6160: Design and preclinical evaluation of a first-in-class covalent reversible inhibitor of IRAK4 with immunomodulatory properties and selective anti-lymphoma effect
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Gema Gorjon de Pablo, Nuria Profitos-Peleja, Miek Jacobs, Aitor Gonzalez-Herrero, Jeronimo Parra, Elisabetta Mereu, Paula Cifuentes, Melissa Orphali, Jordi Teixido, Manel Esteller, Jose I. Borrell, Roger Estrada-Tejedor, Gael Roue
Institution: Josep Carreras Leukaemia Research Institute
Language: English
Topic: NF-κB Signaling Pathways
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4409633766